Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 635 Shares

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German sold 635 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the sale, the chief accounting officer now owns 2,070 shares in the company, valued at $118,445.40. This represents a 23.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rhythm Pharmaceuticals Trading Down 0.4 %

Shares of Rhythm Pharmaceuticals stock opened at $57.74 on Friday. The stock has a 50-day simple moving average of $57.10 and a 200-day simple moving average of $53.89. Rhythm Pharmaceuticals, Inc. has a 52-week low of $35.17 and a 52-week high of $68.58.

Analysts Set New Price Targets

Several equities analysts have weighed in on RYTM shares. JMP Securities reiterated a “market outperform” rating and set a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Oppenheimer started coverage on Rhythm Pharmaceuticals in a report on Friday, December 20th. They set an “outperform” rating and a $76.00 price target on the stock. The Goldman Sachs Group increased their price objective on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Wednesday. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $80.00 target price on shares of Rhythm Pharmaceuticals in a report on Tuesday, November 19th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $68.09.

Institutional Trading of Rhythm Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in RYTM. GF Fund Management CO. LTD. bought a new position in Rhythm Pharmaceuticals during the fourth quarter valued at about $72,000. Voloridge Investment Management LLC increased its holdings in shares of Rhythm Pharmaceuticals by 7.7% during the 4th quarter. Voloridge Investment Management LLC now owns 380,537 shares of the company’s stock valued at $21,302,000 after acquiring an additional 27,214 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of Rhythm Pharmaceuticals by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 13,100 shares of the company’s stock valued at $733,000 after acquiring an additional 300 shares in the last quarter. State of Wyoming acquired a new stake in Rhythm Pharmaceuticals in the 4th quarter worth approximately $61,000. Finally, Stempoint Capital LP boosted its position in Rhythm Pharmaceuticals by 404.1% during the fourth quarter. Stempoint Capital LP now owns 208,016 shares of the company’s stock worth $11,645,000 after purchasing an additional 166,748 shares during the period.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.